A Study of Lanadelumab (SHP643) in Chinese Participants With Hereditary Angioedema (HAE)

A Phase 2 in Adult Subjects With Hereditary Angioedema

NCT06846398 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

A Study of Lanadelumab to Prevent Hereditary Angioedema (HAE) Attacks in Children

NCT04070326 ·Status: COMPLETED ·Phase: PHASE3

A Study in Teenagers and Adults With Hereditary Angioedema (HAE) Type I or Type II Who Use Lanadelumab as Long-Term Prophylaxis

NCT04861090 ·Status: COMPLETED

A Study of Lanadelumab (Takhzyro) and Icatibant (Firazyr®) in Persons With HAE in China

NCT06346899 ·Status: COMPLETED

A Study of Lanadelumab in Teenagers and Adults With Hereditary Angioedema (HAE) in Argentina

NCT04955964 ·Status: COMPLETED

A Study of Lanadelumab in Teenagers and Adults to Prevent Acute Attacks of Non-histaminergic Angioedema With Normal C1-Inhibitor (C1-INH)

NCT04206605 ·Status: COMPLETED ·Phase: PHASE3

A Study in Adults With Hereditary Angioedema (HAE) Who Currently Receive Icatibant at Home

NCT05489640 ·Status: COMPLETED

A Survey of Lanadelumab in Participants With Hereditary Angioedema

NCT05397431 ·Status: ACTIVE_NOT_RECRUITING

Expanded Access for the Prevention of Acute Attacks of 1) Hereditary Angioedema (HAE) in Children and 2) Non-histaminergic Angioedema With Normal C1-Inhibitor (C1-INH) in Teenagers and Adults

NCT04583007 ·Status: NO_LONGER_AVAILABLE

Study to Evaluate Ecallantide in Paediatric Patients With Acute Attacks of Hereditary Angioedema

NCT01253382 ·Status: WITHDRAWN ·Phase: PHASE2/PHASE3

Efficacy, Safety and Immunogenicity Study of Recombinant Human C1 Inhibitor for the Treatment of Acute HAE Attacks

NCT01188564 ·Status: COMPLETED ·Phase: PHASE3

Study to Assess the Tolerability and Safety of Ecallantide in Children and Adolescents With Hereditary Angioedema

NCT01832896 ·Status: WITHDRAWN ·Phase: PHASE2

A Phase 2 HAE Prophylaxis Study With Recombinant Human C1 Inhibitor

NCT02247739 ·Status: COMPLETED ·Phase: PHASE2

Efficacy, Safety and Tolerability of Icatibant for the Treatment of HAE

NCT01457430 ·Status: COMPLETED ·Phase: PHASE4

NTLA-2002 in Adults With Hereditary Angioedema (HAE)

NCT05120830 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2

Study of Oral Deucrictibant Extended-Release Tablet for Prophylaxis Against Angioedema Attacks in Adolescents and Adults With HAE

NCT06669754 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3

Long-Term, Open-label Study of Oral Deucrictibant Extended-Release Tablet for Prophylaxis Against Angioedema Attacks in Adolescents and Adults With HAE

NCT06679881 ·Status: RECRUITING ·Phase: PHASE3

Long-term Safety and Efficacy Study of DX-2930 (SHP643) to Prevent Acute Angioedema Attacks in Patients With Type I and Type II HAE

NCT02741596 ·Status: COMPLETED ·Phase: PHASE3

CSL312_3003 Safety and Pharmacokinetic Study in Subjects 2 to 11 Years of Age With Hereditary Angioedema

NCT05819775 ·Status: COMPLETED ·Phase: PHASE3

STOP-HAE: A Phase 3 Study of ADX-324 in HAE

NCT06960213 ·Status: RECRUITING ·Phase: PHASE3

A Study Investigating the Effectiveness and Safety of Garadacimab for Treating Patients With Hereditary Angioedema (HAE)

NCT07001280 ·Status: RECRUITING

Recombinant Human C1 Inhibitor for the Treatment of Acute Attacks in Patients With Hereditary Angioedema

NCT00225147 ·Status: COMPLETED ·Phase: PHASE2/PHASE3

Dose-ranging Study of Oral PHA-022121 for Acute Treatment of Angioedema Attacks in Patients With Hereditary Angioedema

NCT04618211 ·Status: COMPLETED ·Phase: PHASE2

A Study to Evaluate the Long-term Clinical Safety and Efficacy of Subcutaneously Administered C1-esterase Inhibitor in the Prevention of Hereditary Angioedema

NCT02316353 ·Status: COMPLETED ·Phase: PHASE3

Efficacy and Safety of BCX7353 to Prevent Angioedema Attacks in Subjects With Hereditary Angioedema

NCT02870972 ·Status: COMPLETED ·Phase: PHASE2